靶向cfDNA产前检测在大型临床队列中筛查22q11.2缺失的性能
本研究通过前瞻性多中心入组和储存临床样本,评估靶向cfDNA检测筛查胎儿22q11.2缺失的临床敏感性和特异性。共纳入735例样本,检出46例22q11.2缺失,敏感性69.6%(95%CI 55.2-80.9%),特异性100%(95%CI 99.5-100%)。该检测可检出常见及较小的嵌套缺失,假阳性率低。
要点
- 靶向cfDNA检测筛查22q11.2缺失敏感性69.6%,特异性100%。
- 可检出1.25-3.25 Mb范围的缺失,假阳性率0-0.5%。
- 一般孕妇人群预期PPV在99.5%特异性下为12.2%,99.9%下为41.1%。
核心结论
- 靶向cfDNA检测可检出常见及较小的嵌套22q11.2缺失,假阳性率低(0-0.5%)。
- 研究人群PPV为100%,但一般孕妇人群预期PPV在99.5%特异性下为12.2%,99.9%下为41.1%。
研究设计与样本
- 前瞻性多中心入组有胎儿心脏异常的妊娠及储存临床样本,最终纳入735例临床样本(358例前瞻性入组,377例储存样本)。
- 所有病例均有胎儿遗传学状态(微阵列分析、核型+FISH或类似检测),操作者对胎儿遗传状态盲法。
主要发现
- 46例胎儿22q11.2缺失样本中,32例cfDNA结果提示高概率缺失,敏感性69.6%(95%CI 55.2-80.9%)。
- 689例无22q11.2缺失样本均被正确分类为无缺失证据,特异性100%(95%CI 99.5-100%)。
- 缺失大小范围1.25-3.25 Mb。
关键数值与推荐
- 敏感性69.6%(95%CI 55.2-80.9%),特异性100%(95%CI 99.5-100%)。
- 假阳性率0-0.5%;研究人群PPV 100%;一般人群预期PPV 12.2%(99.5%特异性)或41.1%(99.9%特异性)。
临床怎么用
- 该cfDNA检测可用于筛查胎儿22q11.2缺失,尤其适用于有胎儿心脏异常等高风险妊娠。
- 低假阳性率有助于减少因假阳性导致的母体焦虑和不必要的侵入性操作。
局限性
- 研究样本包括有胎儿心脏异常的前瞻性入组妊娠和储存临床样本,可能影响结果外推。
- 一般孕妇人群的预期PPV基于估算,而非直接观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: 22q11.2 deletion is more common than trisomies 18 and 13 combined, yet no routine approach to prenatal screening for this microdeletion has been established. This study evaluated the clinical sensitivity and specificity of a targeted cell-free DNA (cfDNA) test to screen for fetal 22q11.2 deletion in a large cohort, using blinded analysis of prospectively enrolled pregnancies and stored clinical samples. METHODS: In order to ensure that the analysis included a meaningful number of cases with fetal 22q11.2 deletion, maternal plasma samples were obtained by prospective, multicenter enrolment of pregnancies with a fetal cardiac abnormality and from stored clinical samples from a research sample bank. Fetal genetic status, as evaluated by microarray analysis, karyotyping with fluorescence in-situ hybridization or a comparable test, was available for all cases. Samples were processed as described previously for the Harmony prenatal test, with the addition of DANSR (Digital Analysis of Selected Regions) assays targeting the 3.0-Mb region of 22q11.2 associated with 22q11.2 deletion syndrome. Operators were blinded to fetal genetic status. Sensitivity and specificity of the cfDNA test for 22q11.2 deletion were calculated based on concordance between the cfDNA result and fetal genotype. RESULTS: The final study group consisted of 735 clinical samples, including 358 from prospectively enrolled pregnancies and 377 stored clinical samples. Of 46 maternal plasma samples from pregnancies with a 22q11.2 deletion, ranging in size from 1.25 to 3.25 Mb, 32 had a cfDNA result indicating a high probability of 22q11.2 deletion (sensitivity, 69.6% (95% CI, 55.2-80.9%)). All 689 maternal plasma samples without a 22q11.2 deletion were classified correctly by the cfDNA test as having no evidence of a 22q11.2 deletion (specificity, 100% (95% CI, 99.5-100%)). CONCLUSIONS: The results of this large-scale prospective clinical evaluation of the sensitivity and specificity of a targeted cfDNA test for fetal 22q11.2 deletion demonstrate that this test can detect the common and smaller, nested 22q11.2 deletions with a low (0-0.5%) false-positive rate. Although the positive predictive value (PPV) observed in this study population was 100%, the expected PPV in the general pregnant population is estimated to be 12.2% at 99.5% specificity and 41.1% at 99.9% specificity. The use of this cfDNA test to screen for 22q11.2 deletion could enhance identification of pregnancies at risk for 22q11.2 deletion syndrome without significantly increasing the likelihood of maternal anxiety and unnecessary invasive procedures related to a false-positive result. © 2021 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Bevilacqua E, Jani JC, Chaoui R, et al. Performance of a targeted cell-free DNA prenatal test for 22q11.2 deletion in a large clinical cohort. Ultrasound Obstet Gynecol. 2021. PMID: 34090308. doi:10.1002/uog.23699
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。